Placebo-controlled trial of rituximab in IgM anti-myelin–associated glycoprotein neuropathy

2013200 citationsJournal Articlebronze Open Access

Authors

This study provides Class I evidence that rituximab is ineffective in improving ISS in patients with IgM anti-MAG demyelinating neuropathy.

Good health and well-being

Published in: Neurology

Volume 80, Issue 24, pp. 2217-2225

Field-Weighted Citation Impact: 12.07